Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 64 of 64 publications.

Hale KS, Wang H, Karanth S, Raber MN, Carlson HR, Lenzi R, Abbruzzese JL, Mills GB, Varadhachary GR. Mutation profiling in patients with carcinoma of unknown primary using the Sequenom MassARRAY System. Poster presented at the 2012 ASCO Annual Meeting I; June 2012. [abstract] J Clin Oncol. 2012 May 20; 30(15):4131. doi: 10.1200/jco.2012.30.15_suppl.4131

Goyal RK, Meyer AM, Sheets NC, Federspiel JJ, Carpenter WR, Chen RC, Biddle AK. Cost-utility of proton therapy in the treatment of localized prostate cancer. Poster presented at the 2012 ASCO Annual Meeting I; June 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 May 20; 30(15):e15184.

Keiser J, Nakakura EK, Imhoff L, Mayorga M, Bobiak S, Venook AP, Bergsland EK. Incidence and natural history of bone metastases in neuroendocrine tumors. Poster presented at the 2012 Gastrointestinal Cancers Symposium; February 1, 2012. San Francisco, CA. [abstract] J Clin Oncol. 2012 Feb 1; 30(Number 4_suppl):340. doi: 10.1200/jco.2012.30.4_suppl.340

Choti MA, Mayorga MA, Bobiak S, Kulke M, Yao JC, Bergsland EK, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR. Baseline demographics of patients with neuroendocrine tumors presenting to seven national comprehensive cancer network (NCCN) institutions: development of a multi-institutional outcomes database. Poster presented at the 2012 Gastrointestinal Cancers Symposium; February 1, 2012. [abstract] J Clin Oncol. 2012 Feb 1; 30(Number 4_suppl):187. doi: 10.1200/jco.2012.30.4_suppl.187

Bennett L, Zhao Z, Barber B, Zhou X, Peeters M, Zhang J, Xu F, Wiezorek J, Douillard JY. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 Nov 8; 29(15 Suppl):e19500. doi: 10.1038/bjc.2011.409.

Maurel J, Garcia-Albeniz X, Mendez Mendez C, Martin-Richard M, Pericay C, Vera R, Aparicio J, Rubini M, Cuatrecasas M. PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. Poster presented at the 2011 ASCO Annual Meeting; June 6, 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 Jun; 29(15_suppl). doi: 10.1200/jco.2011.29.15_suppl.tps164

Nooka AK, DeJoubner NJ, Nabhan C, Zhou X, Taylor M, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Levy D, Hirata J, Flowers C. Examination of the follicular lymphoma international prognostic index (FLIPI) in the national LymphoCare study (NLCS): a US patient cohort treated predominantly in community practices. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 3, 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 May 20; 29(15 Suppl):8036. doi: 10.1200/jco.2011.29.15_suppl.8036

Carlson HR, Karanth S, Zarzour MA, Lenzi R, Raber MN, Varadhachary GR. Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: clinicopathologic features and survival data. Poster presented at the 2011 ASCO Annual Meeting; June 2011. [abstract] J Clin Oncol. 2011 May 20; 29(Suppl 15):4123. doi: 10.1200/jco.2011.29.15_suppl.4123

Varadhachary GR, Edmonston TB, Karanth S, Carlson HR, Lebanony D, Rosenwald S, Lenzi R, Spector Y, Cohen D, Raber MN. Prospective gene signature study using microrna to predict the tissue of origin (ToO) in patients with cancer of unknown primary (CUP). Poster presented at the 2010 ASCO meeting; May 2010. [abstract] J Clin Oncol. 2010 May; 28(Suppl 15).

Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008 Feb 20;26(6):925-33.

Watson V, Ryan M. Exploring preference anomalies in double bounded contingent valuation. J Health Econ. 2007 May 1;26(3):463-82. doi: 10.1016/j.jhealeco.2006.10.009

Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005 Jun 1;23(16):3668-75.

Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 1;23(13):2946-54.

Smith T, Hillner B, Neighbors DM, McSorley P, LeChevalier T. An economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol. 1995;13(9):2166-73. doi: 10.1200/JCO.1995.13.9.2166.